P72. Agonists and antagonists of specific serotonergic subreceptors and combined GABAA agonists and NMDA antagonists as a possible treatment of Alzheimers disease

In Alzheimer's disease, neurotransmitter alterations, for example acetylcholine deficiency and a surplus of the excitotoxic glutamate have been described and are associated with cognitive impairment. An interaction between acetylcholine deficiency and beta-amyloid formation has also been reported. Neurotransmitter imbalances between noradrenaline, dopamine and 5-HT on the one hand, and acetylcholine, GABA and glutamate on the other hand have been reported in the temporal cortex and hippocampus. Since serotonin plays an important role in cognitive processes a question arises, whether agonists or antagonists at specific serotonergic subreceptors, for example 5-HT4 or 5-HT7 agonists or 5-HT6 antagonists, can improve cognitive functions.

https://ift.tt/2zokNYX